Flexible dosing to fit your patients’ needs
![Kovaltry logo Kovaltry logo](/sites/g/files/vrxlpx17946/files/2020-02/Kovaltry%20logo.png)
![children and adolscents children and adolscents](/sites/g/files/vrxlpx17946/files/2022-03/children-adolescents.png)
For important safety and use information, please see summary of product characteristics or country-specific prescribing information.
*Dosing for individual patients should be based on patient characteristics.
Recommendations
References
- Kovaltry Summary of Product Characteristics. Leverkusen, Germany: Bayer; 2017. Return to content